(+/-)-N,1-Dibenzyl-3,5-cis-dimethyl-1,2,3,5-tetrahydro-4H-pyrido-[3,4-e][1,4]diazepine-4-carboxamide

ID: ALA3895005

PubChem CID: 132991411

Max Phase: Preclinical

Molecular Formula: C25H28N4O

Molecular Weight: 400.53

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  C[C@@H]1CN(Cc2ccccc2)c2cnccc2[C@H](C)N1C(=O)NCc1ccccc1

Standard InChI:  InChI=1S/C25H28N4O/c1-19-17-28(18-22-11-7-4-8-12-22)24-16-26-14-13-23(24)20(2)29(19)25(30)27-15-21-9-5-3-6-10-21/h3-14,16,19-20H,15,17-18H2,1-2H3,(H,27,30)/t19-,20+/m1/s1

Standard InChI Key:  QGMUDAKKGSLGLA-UXHICEINSA-N

Molfile:  

     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
   11.1088   -3.5996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9079   -5.0084    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3575   -8.2378    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.2455   -9.5315    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0563   -6.9992    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0722   -8.6422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5700   -7.7962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.2096  -10.4595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3496   -7.4204    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4047   -6.8837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6287  -10.8990    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2194   -8.5370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9871   -2.7242    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8354  -10.1043    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2114   -6.0879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7668   -7.4078    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0028  -11.2540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6037   -4.2484    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4027   -5.6572    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.4236   -8.7303    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.7964   -2.8397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2058   -7.0618    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.3915   -7.7883    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7111   -6.4171    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6238   -9.8866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7902   -4.1371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2145  -11.4759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7748   -8.2251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4819   -3.3771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5204   -6.5326    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  9  5  1  0
 22 24  1  0
 14 11  1  0
 27 11  2  0
 10 15  1  6
 26 29  1  0
 19  2  1  0
 28 16  1  0
 22  7  1  0
 24 19  1  0
 18 26  2  0
  7 23  1  6
 18  1  1  0
 25  8  1  0
  4 14  1  0
 29 13  2  0
 21  1  2  0
 28  6  2  0
  5 16  2  0
  3  9  2  0
 12 20  1  0
 20 28  1  0
 20  4  1  0
 10 22  1  0
 13 21  1  0
  6  3  1  0
  7 12  1  0
 24 30  2  0
 14 25  2  0
  2 18  1  0
  8 17  2  0
 10 16  1  0
 17 27  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA3895005

   ---

2. Alternative Forms:

   

   ALA3895005

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 400.53

Molecular Weight (Monoisotopic): 400.2263

AlogP: 4.76

#Rotatable Bonds: 4

Polar Surface Area: 48.47

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 5.45

CX LogP: 4.03

CX LogD: 4.03

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.69

Np Likeness Score: -0.86

References

1. Siegrist R, Pozzi D, Jacob G, Torrisi C, Colas K, Braibant B, Mawet J, Pfeifer T, de Kanter R, Roch C, Kessler M, Corminboeuf O, Bezençon O..  (2016)  Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.,  59  (23): [PMID:27933950] [10.1021/acs.jmedchem.6b01356]

2. Siegrist R, Pozzi D, Jacob G, Torrisi C, Colas K, Braibant B, Mawet J, Pfeifer T, de Kanter R, Roch C, Kessler M, Corminboeuf O, Bezençon O..  (2016)  Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.,  59  (23): [PMID:27933950] [10.1021/acs.jmedchem.6b01356]

3. Das B, Baidya ATK, Mathew AT, Yadav AK, Kumar R..  (2022)  Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,  56  [PMID:35033884] [10.1016/j.bmc.2022.116614]

Source

Source(1):

• Scientific Literature